[ad_1]
- Strategic collaboration advances the detailed study of early, individualized human responses to vaccinations as pharma companies race to deliver safe, effective vaccines sooner
- Combination of medical grade wearables, FDA-cleared AI-based digital platform and immunologic biomarkers establishes individual baselines to detect subtle changes within hours after vaccination
- Correlation between immediate physiological responses, antibody production and cellular immunity will help define new metrics for rapid assessment of successful vaccination
physIQa pioneer in digital medicine, and CellCartaa global leader in precision medicine services, announce a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005256/en/
physIQ and CellCarta launch study to detect vaccine side effects early and help pharma companies potentially bring new vaccinations to market faster. (Graphic: Business Wire)
With enrollment now complete, The VIII (Vaccine-Induced Inflammation Investigation) Study: The “Eight” Study and its Immunologic Response Sub-study seeks to monitor individual differences in physiologic changes associated with immune system activation in patients receiving vaccinations, including those developed to combat diseases such as COVID-19. The study will use blood samples and medical-grade biosensors to continuously monitor and capture remote patient physiology data 24/7. It is made possible through CellCarta’s unique capabilities to comprehensively measure both humoral and cellular immune responses and …
Full story available on Benzinga.com
[ad_2]
Source link
